Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic with millions infected and more than 1 million fatalities. Questions regarding the …

Here, we describe a serological enzyme-linked immunosorbent assay for the screening and
identification of human SARS-CoV-2 seroconverters. This assay does not require the …

In late 2019, cases of atypical pneumonia were detected in China. The etiological agent was
quickly identified as a betacoronavirus (named SARS‐CoV‐2), which has since caused a …

Remodelling of the extracellular matrix (ECM) by ECM metalloproteinases is increasingly
being associated with regulation of immune cell function. ECM metalloproteinases, including …

Combined vaccine formulations targeting not only hemagglutinin but also other influenza virus
antigens could form the basis for a universal influenza virus vaccine that has the potential …

Seasonal influenza viruses constantly change through antigenic drift and the emergence of
pandemic influenza viruses through antigenic shift is unpredictable. Conventional influenza …

Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high
capacity for rapid development. Generation of a universal influenza virus vaccine with the …

Broadly neutralizing antibodies that target epitopes of haemagglutinin on the influenza virus
have the potential to provide near universal protection against influenza virus infection 1 . …

Neuraminidase (NA) is one of the two influenza virus surface glycoproteins, and antibodies
that target it are an independent correlate of protection. However, our current understanding …

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in the city of
Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and …